Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Oct 28, 2020 12:40pm
208 Views
Post# 31796055

RE:Sell-off again....

RE:Sell-off again....I think its fair to be concerned. Hindsight the red flags are there. But stepping back and objectively looking at this, the science has been significantly derisked. Its up to management to monetize this IP. 

I still think this management team can do it, especially if they hire the right "deal guy". But I also think other (better) management teams would have done this faster and not missed so many opportunities. Like I said before, the best time to have uplisted was BEFORE ph2 results announcement.


quote=MasterAlgae]
ATE is not meaningfully impacted by what the TSX or DOW, S&P etc are doing. It is way too small. If anything it has a negative BETA which means ATE moves in the opposite direction of the markets, (proof that it is disconnected). The BETA of Antibe is "inversely correlated to the market benchmark."

It is tax loss selling season, indeed there has been massive selling in ATE since June - obviously.

Given the lack of news from the company and the wider economic environment, individuals' concerns may be rising about ATE, (I know mine are).
[/quote]

Bullboard Posts